Login to Your Account



Pharma: Clinic Roundup


Monday, July 23, 2012
• Bristol-Myers Squibb Co., of New York, said its candidate for liver cancer, brivanib, did not meet its primary overall survival objective based on a noninferiority statistical design in the Phase III BRISK-FL trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription